Patent Issued for Meningococcal B recombinant vaccine (USPTO 12053516).

Sanofi has been issued a patent for a new meningococcal B recombinant vaccine that targets Neisseria meningitidis serogroup B. This vaccine aims to improve coverage against MenB strains and address the limitations of existing vaccines. It includes three recombinant Neisseria proteins and a detergent-extracted outer membrane vesicle from a MenB strain expressing PorA. The vaccine has been shown to elicit a broad immune response with low reactogenic and pro-inflammatory effects. This patent describes the vaccine composition and includes specific claims for the formulation. [Extracted from the article]